ReShape Lifesciences Inc. (NASDAQ: RSLS) has seen a decline in its stock price by -0.51 in relation to its previous close of 0.20. However, the company has experienced a 4.56% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2024-05-17 that ReShape Lifesciences, Inc. (NASDAQ:RSLS ) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Michael Miller – Investor Relatons Paul Hickey – President, CEO & Director Thomas Stankovich – CFO Conference Call Participants Operator Good afternoon, and thank you for joining the ReShape Lifesciences First Quarter 2024 Conference Call. I would like to turn the call over to Michael Miller from Rx Communications.
Is It Worth Investing in ReShape Lifesciences Inc. (NASDAQ: RSLS) Right Now?
Additionally, the 36-month beta value for RSLS is 1.54. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for RSLS is 20.81M and currently, short sellers hold a 1.09% ratio of that float. The average trading volume of RSLS on June 27, 2024 was 5.70M shares.
RSLS’s Market Performance
The stock of ReShape Lifesciences Inc. (RSLS) has seen a 4.56% increase in the past week, with a -5.20% drop in the past month, and a 8.72% gain in the past quarter. The volatility ratio for the week is 9.45%, and the volatility levels for the past 30 days are at 18.48% for RSLS. The simple moving average for the last 20 days is -10.30% for RSLS stock, with a simple moving average of -20.50% for the last 200 days.
RSLS Trading at 2.57% from the 50-Day Moving Average
After a stumble in the market that brought RSLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.13% of loss for the given period.
Volatility was left at 18.48%, however, over the last 30 days, the volatility rate increased by 9.45%, as shares sank -28.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +23.22% upper at present.
During the last 5 trading sessions, RSLS rose by +5.63%, which changed the moving average for the period of 200-days by -77.10% in comparison to the 20-day moving average, which settled at $0.2156. In addition, ReShape Lifesciences Inc. saw -21.11% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RSLS starting from STANKOVICH THOMAS, who sale 131 shares at the price of $0.27 back on Oct 25 ’23. After this action, STANKOVICH THOMAS now owns 22,949 shares of ReShape Lifesciences Inc., valued at $35 using the latest closing price.
STANKOVICH THOMAS, the Chief Financial Officer of ReShape Lifesciences Inc., sale 39 shares at $0.93 during a trade that took place back on Oct 11 ’23, which means that STANKOVICH THOMAS is holding 23,080 shares at $36 based on the most recent closing price.
Stock Fundamentals for RSLS
Current profitability levels for the company are sitting at:
- -1.34 for the present operating margin
- 0.66 for the gross margin
The net margin for ReShape Lifesciences Inc. stands at -1.31. The total capital return value is set at -2.37. Equity return is now at value -177.64, with -88.83 for asset returns.
Based on ReShape Lifesciences Inc. (RSLS), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -58.46. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is 279.6.
Currently, EBITDA for the company is -14.48 million with net debt to EBITDA at 0.19. When we switch over and look at the enterprise to sales, we see a ratio of 0.29. The receivables turnover for the company is 5.32for trailing twelve months and the total asset turnover is 1.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.24.
Conclusion
In conclusion, ReShape Lifesciences Inc. (RSLS) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
